Literature DB >> 12734159

Landiolol, esmolol and propranolol protect from ischemia/reperfusion injury in isolated guinea pig hearts.

Saori Kurosawa1, Noriaki Kanaya, Yukitoshi Niiyama, Masayasu Nakayama, Satoshi Fujita, Akiyoshi Namiki.   

Abstract

PURPOSE: Beta blockers are thought to exert beneficial effects on the ischemic heart. The authors examined the effects of landiolol (ONO 1101), a highly selective beta1 antagonist, propranolol, a nonspecific beta blocker, and esmolol, a selective beta1 antagonist, on postischemic contractile recovery. Drugs were given prophylactically.
METHODS: Ischemia-reperfusion in isolated guinea pig hearts was induced by stopping the perfusion for 45 min and reperfusing for 60 min. Hearts (n = 7 in each group) were treated with or without propranolol (1 or 10 microM), esmolol (5 or 50 microM), or landiolol (20, 100 or 500 microM) ten minutes before inducing ischemia.
RESULTS: At the end of reperfusion, left ventricular pressure (LVP) recovered to 64 +/- 3% of the baseline value in the control group. With 1 and 10 microM propranolol, LVP recovered to 90 +/- 5% and 100 +/- 6% of the baseline value at 60 min after reperfusion, respectively. Fifty microM but not 5 microM of esmolol resulted in restoration of LVP to 97 +/- 17% of the pre-ischemic value at 60 min after reperfusion. In hearts pretreated with 100 and 500 microM landiolol, LVP was restored to 109 +/- 5% and 104 +/- 5% of the baseline value, respectively. Landiolol 100 microM did not depress LVP in the pre-ischemic period.
CONCLUSIONS: The present study shows that landiolol, an ultra-short-acting cardioselective beta1 blocker, has cardioprotective effects on ischemia-reperfusion injury in isolated guinea pig hearts. All three beta blockers were equally protective but the intermediate dosage of landiolol preserved LVP during the pre-ischemic period.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734159     DOI: 10.1007/BF03021062

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  6 in total

1.  Landiolol does not enhance the effect of ischemic preconditioning in isolated rat hearts.

Authors:  Shuchun Yu; Takasumi Katoh; Hisako Okada; Hiroshi Makino; Soichiro Mimuro; Shigehito Sato
Journal:  J Anesth       Date:  2010-01-19       Impact factor: 2.078

2.  Cardioprotective effect and mechanism of action of landiolol on the ischemic reperfused heart.

Authors:  Saori Kimura-Kurosawa; Noriaki Kanaya; Noriko Kamada; Naoyuki Hirata; Masayasu Nakayama; Akiyoshi Namiki
Journal:  J Anesth       Date:  2007-11-01       Impact factor: 2.078

Review 3.  Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

4.  Characteristic interactivity of landiolol, an ultra-short-acting highly selective β1-blocker, with biomimetic membranes: Comparisons with β1-selective esmolol and non-selective propranolol and alprenolol.

Authors:  Hironori Tsuchiya; Maki Mizogami
Journal:  Front Pharmacol       Date:  2013-12-02       Impact factor: 5.810

5.  Postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting or cardiac valve surgery: intraoperative use of landiolol.

Authors:  Kazuhiro Nakanishi; Shinhiro Takeda; Chol Kim; Shusuke Kohda; Atsuhiro Sakamoto
Journal:  J Cardiothorac Surg       Date:  2013-01-24       Impact factor: 1.637

6.  Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol.

Authors:  Monika Skrzypiec-Spring; Joanna Urbaniak; Agnieszka Sapa-Wojciechowska; Jadwiga Pietkiewicz; Alina Orda; Bożena Karolko; Regina Danielewicz; Iwona Bil-Lula; Mieczysław Woźniak; Richard Schulz; Adam Szeląg
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.